巨細胞性動脈炎に対する治療薬としてウパダシチニブ（リンヴォック（R））の承認申請をFDAおよびEMAに提出

References:

1．AbbVie. Data on file ABVRRTI78418.

2．Ameer MA, Peterfy RJ, Khazaeni B. Giant cell arteritis. Updated August 8, 2023. https://www.ncbi.nlm.nih.gov/books/NBK459376/

3．Weyand CM, Goronzy JJ. Immunology of Giant Cell Arteritis. Circ Res. 2023;132(2):238-250. doi:10.1161/CIRCRESAHA.122.322128

4．Giant Cell Arteritis. Arthritis Foundation. Available at: https://www.arthritis.org/diseases/giant-cell-arteritis. Accessed April 11, 2024.

5．RINVOQ [Package Insert]. North Chicago, IL: AbbVie Inc.; 2024.

6．Pipeline – Our Science | AbbVie. 2023. Available at: https://www.abbvie.com/our-science/pipeline.html. Accessed April 17, 2024.

7．A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants with Giant Cell Arteritis (SELECT-GCA). ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT03725202. Accessed April 9, 2024

8．A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants with Takaysu Arteritis (TAK) (SELECT-TAK). ClinicalTrials.gov. Available at: https://clinicaltrials.gov/study/NCT04161898. Accessed April 9, 2024.